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examination of women to support the patient and pro›
vide assistance to the examining doctor, regardless of
the sex of the doctor. Assistance is rarely required in
examination of male patients, who generally do not
express a need for the support of a chaperone and are
likely to feel embarrassed if one is present. Teenagers,
however, are probably more apprehensive about geni›
tal examination than older patients. They are a major
patient group in genitourinary medicine clinics, and
their concerns need to be handled sensitively.
What other factors bear on chaperone use? Doctors
have been accused of unprofessional conduct and
sexual assault after unchaperoned examinations. Eight
per cent of the women sampled by Webb and Opdahl
reported experiences where doctors had conducted a
gynaecological examination in a “less than professional
manner.”4 Unprofessional behaviour involved overexpo›
sure of the woman’s body; inappropriate comments,
gestures, or facial expressions; and being examined in an
unusual position. Eight per cent of the lead physicians in
genitourinary medicine clinics surveyed by Torrance et
al were aware of allegations of unprofessional behaviour
in their departments in the preceding five years.2 For
medicolegal protection therefore a third party should
always be present during genital examination. It is, how›
ever, difficult not to proceed with a clinically indicated
examination if the patient declines a chaperone, provid›
ing the physician feels comfortable in this situation. It
would be prudent to document the patient’s decision for
an unchaperoned examination. It should also be recog›
nised that in a few consultations—for example, the
assessment of sexual dysfunction—the introduction of a
third party for the examination might negatively affect
the doctor›patient relationship.
Variations and inconsistencies in doctors’ attitudes
and practice in the use of chaperones have again been
demonstrated. Examinations need to be conducted in
an atmosphere characterised by sensitivity to patients’
feelings, care, support, and respect for privacy, dignity,
and patient choice. Such qualities are not discretion›
ary. Most female patients in genitourinary medicine
expect, welcome, and receive support from the
presence of a female nurse. Policy should acknowl›
edge this as best practice. Whether chaperoning
should be more frequent during male genital
examination is less clear and needs further study.
Action is needed where practice is suboptimal and
clear policies need to be formulated. Patient
preference, the need for assistance, and medico›
legal considerations would seem to be the major
determining factors.
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Treating behavioural and psychological signs in
Alzheimer’s disease
The evidence for current pharmacological treatments is not strong
Dementia is a prominent healthcare issue for primary
care physicians and specialist services. Over 90% of
patients with dementia experience a “behaviour distur›
bance,”1 often referred to as behavioural or psychologi›
cal signs in dementia in accordance with the
recommendation of the International Psychogeriatric
Association. These symptoms are distressing to
patients and troublesome to carers and often
precipitate admission to residential facilities.1 What is
the evidence that any of the several drugs that are cur›
rently used to treat these symptoms are effective?
Managing the behavioural and psychological signs
of dementia is a major problem for healthcare profes›
sionals. Neuroleptic drugs are the mainstay of pharma›
cological treatment, although their use is justified
largely on the basis of clinical anecdote, and they have
many harmful side effects. These include parkinson›
ism, drowsiness, tardive dyskinesia, falls, accelerated
cognitive decline,2 and severe neuroleptic sensitivity
reactions.3 It is therefore not surprising that the chief
medical officer has recommended judicious use of
these agents in patients with dementia.4
In 1990 Schneider published a landmark study
showing the paucity of large, placebo controlled,
double blind trials of neuroleptic agents in treating
behavioural and psychological signs in dementia.5
Since then research in the subject has increased, but
most treatment studies have used an open or active
comparison design, a major methodological flaw given
the high placebo response rates (40%).5 Two large
multicentre studies with risperidone have recently
been completed,6 showing a significant advantage
over placebo for overall reduction of behaviour
disturbances, although in one of the studies psychotic
symptoms did not improve significantly. In addition,
psychosis and aggression responded preferentially to
different doses. The studies of neuroleptic agents
are summarised in the table on the BMJ ’s website
(www.bmj.com).
There is a tendency in clinical trials to group
together different behavioural and psychological signs,
although they are likely to have separate neurochemi›
cal or neurophysiological bases. For example, there is
evidence linking visual hallucinations to cholinergic
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depletion,7 but delusions are linked to relative
preservation of the parahippocampal gyrus,8 while
aggressive behaviour is related to abnormalities of
serotonergic function.9 As these phenomena are
disparate, they may respond to different agents or dif›
ferent doses of the same agents. In practice many
patients with dementia have more than one type of
behavioural or psychiatric symptom, but it should be
possible to undertake separate studies focusing on
common disturbances such as aggression or psychosis
when they are clinically important and represent the
most problematic behavioural or psychological symp›
tom for that individual patient.
Most intervention trials for behavioural or psycho›
logical signs in dementia have a duration of less than
three months. In this time frame low doses of
neuroleptic drugs are well tolerated, but the issues of
longer term efficacy and safety are not addressed. For
example, one prospective study following a research
cohort of patients with dementia has suggested that
neuroleptic agents might hasten cognitive decline,2
while another found no differences in the persistence
of psychotic symptoms over one year in patients taking
or not taking antipsychotic medication.10 Furthermore,
the high placebo response rates5 and the spontaneous
resolution of psychotic symptoms within three
months10 among many sufferers indicates that a
substantial proportion of patients may not require
pharmacological treatment.
Clinical trials, mainly with an open design, have
also been undertaken with a wide range of non›
neuroleptic treatments including anticonvulsants and
trazadone, as well as non›pharmacological treatments
such as carer training or sensory inputs.11 Again these
trials have generally been small and have clustered
together different behavioural and psychological signs.
In the few preliminary studies which have been
conducted carbamazepine and trazadone appear to be
as effective as neuroleptics,11 although the main areas
of improvement are agitation, aggression, and restless›
ness, rather than psychosis.
Encouraging data are starting to emerge from the
secondary analysis of trials involving cholinesterase
inhibitors, suggesting that 50% or more of patients
with psychotic symptoms experience improvement.11
Placebo response rates are, however, high, and the
patients were recruited because of cognitive impair›
ment not because of psychotic symptoms. Although
this does not constitute evidence of efficacy, it indicates
the need for specific intervention trials.
Dementia is a common condition, and sufferers
have a particularly high risk of adverse treatment
responses, so it is important to have clear evidence that
treatments are both effective and safe. There is an
urgent need for double blind trials focusing on specific
behavioural or psychological signs in dementia, with
designs that allow for the high rates of spontaneous
remission, especially studies using cholinesterase
inhibitors and non›pharmacological intervention
strategies.
Given current knowledge, unless symptoms are
extremely distressing it would seem appropriate to
monitor the disturbances for at least one month before
starting pharmacological treatments. The monitoring
period allows time for spontaneous resolution, while
psychosocial interventions may facilitate better practi›
cal management or evoke key elements from the very
pronounced “placebo” response. Better evidence is
required before individual pharmacological agents are
licensed specifically for managing behavioural or
psychological signs in dementia.
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Saving lives or sustaining the public’s health?
The English white paper is stronger on disease than it is on health
England’s long awaited public health white paper,Saving Lives: Our Healthier Nation,1 has finallyappeared over a year after publication of the
green paper.2 The British prime minister has written
the foreword and 12 ministers have signed the
preface—symbols of the relative importance of the
health strategy and the importance attached to cross
government working. But the title, Saving Lives, the
headline target to prevent 300 000 deaths, and the
proposal to introduce defibrillators in public places
seem to emphasise narrow, disease based health care
over wider public health concerns.
The four priority areas remain the same as in the
green paper: coronary heart disease and stroke;
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